The Phase 3 AURORA trial of Descartes-08 for myasthenia gravis (MG) is progressing, with topline data expected in 1Q27. The company plans to file a biologics license application (BLA) in mid-2027, supporting a potential path toward regulatory review. Overall, the update is modestly positive but event timing is still out into 2027.
The Phase 3 AURORA trial of Descartes-08 for myasthenia gravis (MG) is progressing, with topline data expected in 1Q27. The company plans to file a biologics license application (BLA) in mid-2027, supporting a potential path toward regulatory review. Overall, the update is modestly positive but event timing is still out into 2027.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
